NCT00976508View on ClinicalTrials.gov

Figitumumab Combined With Pegvisomant For Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

September 30, 2011

Study Completion Date

October 31, 2012

Conditions
Colorectal NeoplasmsLung NeoplasmsBreast NeoplasmsProstatic NeoplasmsSarcoma
Interventions
DRUG

figitumumab

IGF-1R antibody, 20 mg/kg, IV every 3 weeks for up to 1 year

DRUG

pegvisomant

growth hormone antagonist, 10, 20 or 30 mg per day via subcutaneous injection for up to 1 year

Trial Locations (5)

48149

Pfizer Investigational Site, Münster

55455

Pfizer Investigational Site, Minneapolis

55905

Pfizer Investigational Site, Rochester

H3T 1E2

Pfizer Investigational Site, Montreal

00290

Pfizer Investigational Site, Helsinki

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY